US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Electra Therapeutics / Equity Capital Markets

<ul>
<li>Electra Therapeutics is targeting a $303 million IPO to advance ipsoprubart through Phase 2/3 development in sHLH and expand its precision immune-cell depletion platform.</li>
<li>Ipsoprubart has shown compelling early efficacy, including 100% eight-week survival and response rates in 12 frontline malignancy-associated HLH patients.</li>
<li>A constructive biotech IPO backdrop and strong underwriting syndicate provide a favorable setup, with Electra offering an attractive risk-reward profile ahead of Friday’s debut.</li>
</ul>


Electra Therapeutics is targeting a $303 million IPO to advance ipsoprubart through Phase 2/3 development in sHLH and expand its precision immune-cell depletion platform.
Ipsoprubart has shown compelling early efficacy, including 100% eight-week survival and response rates in 12 frontline malignancy-associated HLH patients.
A constructive biotech IPO backdrop and strong underwriting syndicate provide a favorable setup, with Electra offering an attractive risk-reward profile ahead of Friday’s debut.


Electra Therapeutics (ETRA): Precision Immune-Cell Depletion Biotech Sets Terms for Same-Week Debut

ADARx Pharmaceuticals / Equity Capital Markets

<ul>
<li>ADARx targets a $1.5–$1.7 billion valuation with a $15–$17 IPO range and 21.875 million shares offered.</li>
<li>AbbVie’s up to $100 million concurrent investment provides a strategic validation point alongside ADARx’s late-stage siRNA pipeline.</li>
<li>Proceeds will fund multiple clinical programs, led by Phase 3 onvuzosiran and Phase 2 agazisiran development.</li>
</ul>


ADARx targets a $1.5–$1.7 billion valuation with a $15–$17 IPO range and 21.875 million shares offered.
AbbVie’s up to $100 million concurrent investment provides a strategic validation point alongside ADARx’s late-stage siRNA pipeline.
Proceeds will fund multiple clinical programs, led by Phase 3 onvuzosiran and Phase 2 agazisiran development.


ADARx Pharmaceuticals (ADRX):  ADARx Sets Terms, Targets Up to $372m in IPO, AbbVie Alongside

United States

Electra Therapeutics, Inc. is a biopharmaceutical company. The Company develops precision medicines for the treatment of immune-mediated diseases and cancer. Electra Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Electra Therapeutics (ETRA US)

Electra Therapeutics (ETRA): Precision Immune-Cell Depletion Biotech Sets Terms for Same-Week Debut

Electra Therapeutics Looks to Ride Biotech IPO Momentum With $300M Offering. Jefferies, TD Cowen, Evercore ISI, Cantor are among the underwriters...

IPO Boutique

ADARx Pharmaceuticals (ADRX): ADARx Sets Terms, Targets Up to $372m in IPO, AbbVie Alongside

DARx brings a late-stage siRNA pipeline, a major AbbVie investment and multiple shots on goal into a biotech IPO window that needs a strong debut.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)